Company
Headquarters: Xinyang, China
Employees: 2,604
CN¥12.20 Billion
CNY as of Jan. 1, 2025
US$1.67 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Henan Lingrui Pharmaceutical Co., Ltd. produces and sells medicines in China. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, tinctures, etc. covering approximately 100 product varieties. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, Shenqi Hypoglycemic capsules, and others. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is based in Xinyang, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥3.56 B |
| EBITDA | CN¥796.6 M |
| Gross Profit TTM | CN¥2.62 B |
| Profit Margin | 18.96% |
| Operating Margin | 21.00% |
| Quarterly Revenue Growth | 5.80% |
Henan Lingrui Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600285 wb_incandescent